Literature DB >> 19077712

Vasculitis: lessons learned.

Philip Seo.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19077712      PMCID: PMC2896030          DOI: 10.1097/BOR.0b013e32831e4250

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


× No keyword cloud information.
  12 in total

1.  Diagnosis of Wegener's granulomatosis in the ANCA era.

Authors:  Mustafa Al Maini; Simon Carette
Journal:  J Rheumatol       Date:  2006-10       Impact factor: 4.666

Review 2.  Involvement of the heart by small and medium vessel vasculitis.

Authors:  Garvan C Kane; Karina A Keogh
Journal:  Curr Opin Rheumatol       Date:  2009-01       Impact factor: 5.006

3.  An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients.

Authors:  E Reinhold-Keller; N Beuge; U Latza; K de Groot; H Rudert; B Nölle; M Heller; W L Gross
Journal:  Arthritis Rheum       Date:  2000-05

4.  Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).

Authors:  Philip Seo; Yuan-I Min; Janet T Holbrook; Gary S Hoffman; Peter A Merkel; Robert Spiera; John C Davis; Steven R Ytterberg; E William St Clair; W Joseph McCune; Ulrich Specks; Nancy B Allen; Raashid A Luqmani; John H Stone
Journal:  Arthritis Rheum       Date:  2005-07

Review 5.  Vasculitis in rheumatoid arthritis.

Authors:  Carl Turesson; Eric L Matteson
Journal:  Curr Opin Rheumatol       Date:  2009-01       Impact factor: 5.006

Review 6.  Thromboembolic disease in vasculitis.

Authors:  Gunnar Tomasson; Paul A Monach; Peter A Merkel
Journal:  Curr Opin Rheumatol       Date:  2009-01       Impact factor: 5.006

Review 7.  Imaging for large-vessel vasculitis.

Authors:  Daniel Blockmans; Thorsten Bley; Wolfgang Schmidt
Journal:  Curr Opin Rheumatol       Date:  2009-01       Impact factor: 5.006

Review 8.  Advances in the use of biologic agents for the treatment of systemic vasculitis.

Authors:  Sharon A Chung; Philip Seo
Journal:  Curr Opin Rheumatol       Date:  2009-01       Impact factor: 5.006

9.  The future of damage assessment in vasculitis.

Authors:  Philip Seo; Raashid A Luqmani; Oliver Flossmann; Bernhard Hellmich; Karen Herlyn; Gary S Hoffman; David Jayne; Cees G M Kallenberg; Carol A Langford; Alfred Mahr; Eric L Matteson; Chetan B Mukhtyar; Tuhina Neogi; Abraham Rutgers; Ulrich Specks; John H Stone; Steven R Ytterberg; Peter A Merkel
Journal:  J Rheumatol       Date:  2007-06       Impact factor: 4.666

10.  The end of the disease era.

Authors:  Mary E Tinetti; Terri Fried
Journal:  Am J Med       Date:  2004-02-01       Impact factor: 4.965

View more
  3 in total

1.  Rhinologic and sinonasal changes in PR3 ANCA pulmonary vasculitis.

Authors:  Katarzyna Zycinska; K A Wardyn; E Piotrowska; T M Zielonka; H Zycinski; A Bogaczewicz; A Nitsch-Osuch; M Miskiewicz; R Smolarczyk
Journal:  Eur J Med Res       Date:  2010-11-04       Impact factor: 2.175

2.  Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement.

Authors:  K Zycinska; K A Wardyn; T M Zielonka; R Krupa; W Lukas
Journal:  Eur J Med Res       Date:  2009-12-07       Impact factor: 2.175

3.  Clinical implications of serum thrombomodulin in PR3-ANCA-associated vasculitis.

Authors:  K Zycinska; K A Wardyn; T M Zielonka; R Krupa; W Lukas
Journal:  Eur J Med Res       Date:  2009-12-07       Impact factor: 2.175

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.